

## RESEARCH ARTICLE

Editorial Process: Submission:10/22/2024 Acceptance:06/04/2025

# Anti- Cancer Potential of Diosgenin, a Steroidal Saponin, against Human Oral Cancer Cells

Uma Dutta<sup>1\*</sup>, Sonali Dey<sup>1</sup>, Monikongkona Boruah<sup>2</sup>, Bethsebie Laldusaki Sailo<sup>3</sup>, Bhaigyaroti Muchahary<sup>1</sup>, Ajaikumar B. Kunnumakkara<sup>3</sup>

### Abstract

**Objective:** Oral squamous cell carcinoma (OSCC), affecting the lip and oral cavity, is one of the most prevalent cancers worldwide with the highest morbidity rate in the North-Eastern region of India. The current treatment options including surgery and chemotherapy are plagued by adverse side-effects and emergence of chemo-resistance, particularly against drugs like cisplatin and 5-fluorouracil. The present study focuses on demonstrating the effects of diosgenin, a naturally occurring steroidal saponin, on the survival, proliferation, and migration of OSCC cells *in vitro*. **Methods:** Preliminary *in vitro* screening of diosgenin in OSCC cells was performed using MTT, colony formation, cell cycle arrest, PI-FACS, live/dead, and wound-healing assays. In addition, the potential of diosgenin in regulating the expression of critical proteins involved in OSCC was evaluated using western blot analysis. **Result:** The present study shows that diosgenin exhibited selective anti-proliferative activity on OSCC cell lines SAS and HSC3 compared to normal kidney cell line HEK-293T. In addition, it enhances the chemosensitivity of SAS cells to cisplatin and 5-FU. This compound also displayed anti-clonogenic, cell cycle arrest, cytotoxic, and anti-migratory effects on SAS cells in a dose-dependent manner. Further, diosgenin regulated the expressions of *COX-2*, *CXCR-4*, *VEGF*, *TWIST-1*, *p-AKT*, and *AKT*, which are critical proteins for the development and progression of OSCC. **Conclusion:** These findings support the therapeutic potential of diosgenin, thereby opening a new avenue for oral cancer therapy. Nonetheless, the data needs to be further validated in *in vivo* and clinical settings.

**Keywords:** OSCC- diosgenin- chemosensitivity- cisplatin- 5-fluorouracil

*Asian Pac J Cancer Prev*, 26 (6), 2049-2059

### Introduction

Oral cancer refers to malignant neoplasms that develop on the lips or within the oral cavity [1]. Since 90% of malignant tumors in dentistry originate from squamous cells, it is most commonly referred to as oral squamous cell carcinoma (OSCC) [2]. Globally, oral cancer is one of the most common types of cancer, with nearly one-third of all cases occurring in India. Additionally, India holds the second-highest number of OSCC cases among countries globally [3]. The buccal mucosa accounts for about 32% of oral cancer cases, followed by the tongue (22%), lower lip (11%), palate (11%), vestibule (8%), alveolus (5%), floor of the mouth (5%), and gingiva (3%) [4].

Oral carcinogenesis is an intricate and multifactorial process involving both genetic and environmental risk factors [5]. It occurs when various genetic mutations in epithelial cells lead to the accumulation of genetic and epigenetic alterations in oncogenes and/or tumor suppressor genes [6]. Two widely established risk

factors that are independent of one another are alcohol consumption and tobacco products for oral cancer and oral potentially malignant disorders [7]. Tobacco, alcohol usage or human papillomavirus infections can result in genetic alterations which trigger the stromal cell transformation, immunological suppression and persistent inflammation [8]. Currently, available treatments for OSCC include surgery, radiation therapy, and chemotherapy or a combination of these, based on pathological findings and disease grade. However, these treatment modalities often come with adverse side-effects, development of chemo-resistance, and sometimes even recurrence [9]. Thus, the need arises to identify natural compounds that are safe, efficacious and cost-effective for the treatment of OSCC.

The utilization of natural products, particularly steroid compounds, has been gaining increasing attention, both as therapeutic agents and as lead compounds in drug development approaches [10]. Amongst these compounds, diosgenin (3-hydroxy-5-spirostene) is a well-known

<sup>1</sup>Cell and Molecular Biology, Toxicology Laboratory, Department of Zoology, Cotton University, Guwahati, Assam, India.

<sup>2</sup>Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. <sup>3</sup>Department of Biosciences and Bioengineering, Indian Institute of Technology, Guwahati, Assam, India. \*For Correspondence: uma.dutta@cottonuniversity.ac.in

steroidal saponin, which is obtained by hydrolysis of the saponin dioscin. Diosgenin, a phytosterol saponin, is a substantial bioactive component present in the roots of wild yam (*Dioscorea villosa*) and the seeds of fenugreek (*T. foenum-graecum*) [11]. Various ethnic communities living in North-East India have incorporated yams into their diet and medicinal practices [12]. Several studies have showed that the tubers of *Dioscorea* are utilized for addressing a range of health issues including fever, headache, dysentery [13], gastrointestinal disorders, abdominal discomfort, wounds, cough, among others [14, 15]. Various plant species, such as *Costus speciosus*, *Smilax menispermoides*, species of *Paris*, *Aletris*, *Trillium*, and *Dioscorea*, contain high concentrations of diosgenin [16]. According to Nguyen et al. [17], saponinins are a class of compounds commonly found in natural products in their glycoside form and contribute to overall health. Steroidal saponinins, also known as spirostans, are among the most potent bioactive substances derived from natural sources. Most steroidal saponinins exhibit anti-cancer activity *in vitro* and in preclinical animal models, along with a broad range of pharmacological properties. Numerous studies have demonstrated diosgenin's diverse biological activities, including cholesterol-lowering, anti-inflammatory, antiproliferative, blood sugar-lowering, and potent antioxidant effects [18]. In 2010, Jung et al. observed that murine macrophages produced reduced levels of inflammatory chemicals, including nitric oxide and interleukins 1 and 6 when pre-exposed to diosgenin and then stimulated with lipopolysaccharide/interferon- $\gamma$  [19]. Diosgenin has also demonstrated strong inhibition of continuously active inflammatory and survival-promoting signaling pathways in various cancer cells, leading to apoptosis [20]. Additionally, it has been noted that diosgenin prevents Tumor Necrosis Factor- $\alpha$  (TNF- $\alpha$ )-induced Nuclear Factor Kappa B (NF- $\kappa$ B) activation and hinders osteoclast formation in RAW 264.7 macrophage cells [21]. Since, diosgenin has already displayed a wide range of biological activities, this study aimed to evaluate the anti-cancer activity of this compound against OSCC cells.

## Materials and Methods

### Reagents

Diosgenin was obtained from TCI, Japan. 5-Fluorouracil (5-FU) and Cisplatin were obtained from Sigma Aldrich, USA. A 50 mM stock solution of diosgenin was prepared in dimethyl sulfoxide (DMSO) (Merck Life Sciences Pvt. Ltd.). 10 mM stock of 5-FU was prepared in sterile MilliQ water and 100 mM cisplatin stock was prepared in saline water. Penicillin-streptomycin (Penstrep), Dulbecco's minimum essential medium (DMEM), and fetal bovine serum (FBS) were sourced from Gibco, USA. MTT and propidium iodide (PI) were purchased from Sigma Aldrich, USA. Antibodies against *AKT*, *pAKT*, *COX-2*, *CXCR-4*, *VEGF*, and  *Twist-1* were acquired from Cell Signaling Technologies, USA. The live and dead assay kit was obtained from Invitrogen, USA. Bovine serum albumin (BSA) and crystal violet was obtained from HiMedia, India and SRL Pvt. Ltd., India.

Prestained marker, Bradford reagent, and Clarity Western ECL Substrate was purchased from BioRad Laboratories.

### Cell lines

Human OSCC cells, SAS was obtained from Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, India. HSC3 cell line was generously provided by Dr. Renu Wadhwa from the National Institute of Advanced Industrial Science and Technology (AIST), Japan and human normal embryonic kidney cells, HEK-293T was gifted by Dr. Suresh Kumar Rayala, Indian Institute of Technology Madras, India. The cells were cultured in DMEM, supplemented with 10% FBS and 1% Penstrep and incubated at 37°C in a humidified chamber with 5% CO<sub>2</sub> until reaching 60% to 70% confluence.

### Cell proliferation assay

The effect of diosgenin on OSCC cells was evaluated using an MTT assay. Briefly, 2x10<sup>3</sup> cells per well were plated in 96-well plates and incubated for 18–24 hours at 37°C. They were then treated with diosgenin at concentrations of 0, 10, 25, 50, 75 and 100  $\mu$ M and incubated for 0 and 72 hours. Each well received 10  $\mu$ l of a 5 mg/ml MTT solution and was incubated for 2 hours. After removing the growth media, 100  $\mu$ l of DMSO was added to each well to dissolve the MTT-formazan product, which was then incubated for 1 hour at room temperature. Absorbance of the colored solution was measured at 570 nm using a microplate reader (TECAN Infinite 200 PRO multimode reader). The percentage of cell proliferation, indicating the growth inhibition caused by diosgenin, was assessed for SAS, HSC3, and HEK-293T cells.

Similarly, *in vitro* drug sensitivity of Cisplatin and 5-FU was also assessed by MTT assay. To investigate the effect of diosgenin in combination with Cisplatin and 5-FU, SAS cells were treated with different concentrations of diosgenin (15 and 30  $\mu$ M), Cisplatin (150 and 200  $\mu$ M), 5-FU (1 and 2  $\mu$ M) and in combination – Diosgenin:Cisplatin (15 $\mu$ M:150 $\mu$ M, 15 $\mu$ M:200 $\mu$ M, 30 $\mu$ M:150 $\mu$ M, 30 $\mu$ M:200 $\mu$ M), Diosgenin:5FU (15 $\mu$ M:1 $\mu$ M, 15 $\mu$ M:2 $\mu$ M, 30 $\mu$ M:1 $\mu$ M, 30 $\mu$ M:2 $\mu$ M), for 72 hours.

The percentage of cell proliferation was obtained by using the following equation [22]:

$$\% \text{ proliferation} = \frac{\text{A570 of treated cells}}{\text{A570 of untreated cells}} \times 100$$

### Colony formation assay

The clonogenic capacity of OSCC cells treated with diosgenin was assessed using a colony formation assay. In brief, SAS cells were plated at a low density (approximately 5x10<sup>2</sup> cells per well) in 6-well plates and treated with diosgenin for 24 hours at specified concentrations (0, 5, 50  $\mu$ M). After treatment, the medium was replaced with fresh medium, and the cells were incubated for 10 days. Following this, the plates were fixed with 70% ethanol and stained with 0.5% crystal violet. The survival fraction was determined by quantifying images of each well using ImageJ software.

*Cell cycle analysis by flow cytometry*

For measurement of cellular DNA content, flow cytometric analysis was performed. Briefly, the cells were plated in 6-well plates in the concentration of  $1 \times 10^5$  cells per well and allowed to incubate overnight. Cells were exposed to different concentrations of diosgenin (0, 20, and 40  $\mu\text{M}$ ). After drug treatment, both adhered and suspended cells were harvested, washed with PBS and fixed in 70% ethanol at  $-20^\circ\text{C}$  overnight. Cells were washed twice by ice cold PBS and incubated in PI-RNase solution at room temperature for 30 min in dark. The cell cycle stages in drug-treated groups in comparison with control were measured by flow cytometric analysis (Becton- Dickinson, San Jose, CA). The percentage of cells residing in different phases of cell cycle was determined by fitting the model using FCS Express software.

*PI- flow cytometric assay*

PI, a fluorescent dye that binds to nucleic acids and produces red fluorescence, was employed in flow cytometry to assess cell viability [23]. SAS cells were plated in 6-well dishes with a density of  $1 \times 10^5$  cells per well, allowed to incubate for 24 hours, and subsequently treated with specified concentrations of diosgenin (0, 25, 50, and 100  $\mu\text{M}$ ) for 72 hours. Following treatment, all cells were collected, rinsed with PBS, and exposed to 5  $\mu\text{l}$  of 1 mg/ml PI. After a 10-minute incubation, the impact of diosgenin on the cells was examined using flow cytometric analysis (Becton- Dickinson, San Jose, CA). Viable cells, characterized by intact cell membranes, exhibit low PI permeability and emit minimal fluorescence, while dead cells display heightened red fluorescence due to damaged plasma membranes.

*Live/Dead assay*

To assess diosgenin induced cytotoxicity, a live/dead assay was conducted to evaluate intracellular esterase activity and plasma membrane integrity. Calcein-AM, a non-fluorescent polyanionic dye, is retained by viable cells, leading to intense green fluorescence upon enzymatic (esterase) conversion. Additionally, ethidium homodimer enters the cells with damaged membranes, binds to nucleic acids and generates bright red fluorescence in dead cells [24]. Briefly,  $2 \times 10^3$  cells per well were incubated to specified concentrations of diosgenin (0, 50 and 75  $\mu\text{M}$ ) for 48 hours at  $37^\circ\text{C}$ . Subsequently, cells were stained with 10  $\mu\text{l}$  live/dead reagent and incubated at  $37^\circ\text{C}$  for 20 minutes. Cells were then analysed using an inverted fluorescence microscope (Olympus, Japan).

*Scratch wound healing assay*

This assay is conducted to assess cell migration by creating an artificial gap in a confluent cell monolayer, and then monitoring the migration of cells from the edges over time [25]. The extent and rate of scratch wound healing reflect the migratory capabilities of the cells. A total of  $2 \times 10^5$  cells per well were seeded in 6-well plates and cultured until a confluent monolayer (95%) was established. After monolayer formation, the medium was replaced with serum-free medium, and the cells were

incubated for 8 hours. Subsequently, the medium was aspirated, and a 200  $\mu\text{l}$  pipette tip was used to create a wound in the midline of the culture well. Following this, cells were washed twice with PBS to eliminate any debris. The cells were then exposed to specified concentrations of diosgenin (0, 30, and 50  $\mu\text{M}$ ). Migration was assessed by observing changes in the scratch wound area using an inverted microscope (Nikon T1-SM, Japan). Images were captured at 0 and 24 hours and analyzed using ImageJ software.

*Western blot analysis*

Western blotting was performed to investigate the effect of diosgenin in regulating the expression level of different proteins involved in the development and progression of OSCC. SAS cells were seeded in 6- well plates ( $2 \times 10^5$  cells per well) and following overnight incubation, the cells were treated with indicated concentrations of diosgenin (0, 30, 50, and 75  $\mu\text{M}$ ) for 24 hours. The cells were lysed in ice cold lysis buffer. The cell lysates were centrifuged at 13000 rpm for 10 minutes to recover the supernatant. The supernatant containing proteins was taken as the cell extract and the protein concentration was quantified using Bradford assay. The extract containing equal amount of protein were subjected to 10% Sodium Dodecyl Sulphate –Polyacrylamide gel electrophoresis (SDS-PAGE). The resolved proteins were electro-transferred to a nitrocellulose membrane and protein bands were visualized by staining with Ponceau S Stain. The membrane was incubated in blocking buffer containing 5% milk for 2 hours, washed with 1xTBST three times and then probed with primary antibody overnight at  $4^\circ\text{C}$ . Afterwards, membranes were washed in TBST three times, and then with an appropriate peroxidase- conjugated secondary antibody at room temperature for 1 hour. The expression of proteins was detected by enhanced chemiluminescent (ECL) reagent [26].

*Statistical analysis*

Statistical analyses were performed using Student's t-test. Results are presented as mean  $\pm$  standard deviation (SD) with a p-value of  $< 0.05$  vs. control, considered statistically significant. All analyses were conducted and graphs were plotted using Microsoft Office Excel Version 2015.

**Results***Anti-proliferative effect of diosgenin on SAS and HSC3 cells*

We first examined whether diosgenin affected the cell proliferation of OSCC cells, SAS and HSC3, and human embryonic kidney epithelial cells, HEK-293T, using the MTT assay. The results demonstrated that treatment with diosgenin at concentrations below 25  $\mu\text{M}$  for 72 hours did not significantly affect the proliferation of SAS and HSC3 cells. However, at 100  $\mu\text{M}$ , diosgenin effectively reduced SAS cell proliferation, indicating a strong cytotoxic effect (Figure 1). The  $\text{IC}_{50}$  value for SAS cells was determined to be 31.7  $\mu\text{M}$ . Similarly, diosgenin inhibited the proliferation of HSC3 cells with an  $\text{IC}_{50}$  value of 61  $\mu\text{M}$ .




Figure 1. Effect of Diosgenin on the Proliferation of SAS, HSC3, and HEK-293T Cells Using MTT Assay. Cells were treated with 0, 10, 25, 50, 75 and 100 µM diosgenin for 72 hours. %Proliferation for control was taken as 100%. Data is presented as mean  $\pm$  SD, \* $p < 0.05$  vs. control.

However, diosgenin did not cause significant cytotoxicity in normal human embryonic kidney epithelial cells (HEK-293T), suggesting a selective effect on cancer cells. As diosgenin demonstrated stronger cytotoxic effect and more effective inhibition of cell proliferation in SAS cells than in HSC3 cells, all further experiments were conducted using the SAS cell line.

#### *Chemosensitizing effect of diosgenin in combination with 5-FU and cisplatin on SAS cells*

The proliferation of the SAS cell was significantly decreased by diosgenin when treated in combined doses of cisplatin and 5-FU (Figure 2 a and b). The data indicated that treatment with diosgenin and 5-FU at a dose of 30 µM and 2 µM respectively and diosgenin and cisplatin at a dose of 30 µM and 200 µM respectively, caused higher cytotoxicity to SAS cells. Treatment of SAS cells with

diosgenin shows enhanced cytotoxicity when combined with chemotherapeutic drugs 5-FU and cisplatin as compared to when it is used alone.

#### *Effect of diosgenin on the clonogenic property of SAS cells*

To investigate the effect of diosgenin on the clonogenic potential of SAS cells, a colony formation assay was performed. After exposure to different concentrations of diosgenin, the colony-forming ability of both SAS cells was suppressed in a dose-dependent manner (Figure 3). These results revealed that diosgenin reduced the clonogenic potential of SAS cells in dose dependent manner.

#### *Effect of diosgenin in inducing cell cycle arrest in SAS cells*

To evaluate the effect of diosgenin on the phases of the cell cycle of SAS cells, flow cytometry-based cell cycle




Figure 2. Effect of Diosgenin on the Proliferation of SAS Cells in Combination with (a) Cisplatin, (b) 5-FU. Cells were treated with diosgenin (15 and 30 µM), Cisplatin (150 and 200 µM), 5-FU (1 and 2 µM) and in combination – diosgenin:Cisplatin (15µM:150µM, 15µM:200µM, 30µM:150µM, 30µM:200µM), diosgenin:5FU (15µM:1µM, 15µM:2µM, 30µM:1µM, 30µM:2µM), for 72 hours. %Proliferation for control was taken as 100%. Data is presented as mean  $\pm$  SD, \* $p < 0.05$  vs control.






Figure 3. Effect of Diosgenin on the Clonogenic Property of SAS Cells. (a) SAS cells were treated with diosgenin: 0, 5, 50 µM for 24 hours and monitored for up to 10 days for colony formation; (b) Survival fraction vs control for SAS cells were plotted. Data is presented as mean  $\pm$  SD, \* $p$  < 0.05 vs control.

analysis was performed at two different doses – 20 and 40 µM. The results showed that diosgenin induced cell cycle arrest at the S-phase of the cell cycle which led to an increase in the S-phase subpopulation and a decrease in the G1 and G2/M phase subpopulation (Figure 4). The effect was more pronounced at 40 µM concentration.

#### Effect of diosgenin in inducing cell death in SAS cells

In order to evaluate the potential of diosgenin in inducing cell death in SAS cells, PI-FACS analysis was performed. It was observed that diosgenin exhibited a dose dependent cytotoxicity, with more than 50 % cell death at 100 µM concentration (Figure 5 a and b). The same has been visually evident from the live/dead staining assay, where diosgenin treatment for 48 hours caused a dose-dependent toxic effect on SAS cells (Figure 5 c).

#### Effect of diosgenin in inhibiting the migration of SAS cells

Diosgenin was observed to inhibit the migration of SAS cells into the denuded area at a concentration of 30 and 50 µM after 24 hours of incubation. These results indicated that diosgenin significantly reduced the motility of SAS cells at 50 µM (Figure 6).

#### Effect of diosgenin in regulating the expression of different proteins involved in SAS cells

In the cells treated with diosgenin, downregulation of the following proteins was observed: *COX-2*, *CXCR-4*, *VEGF*, *TWIST-1*, *p-AKT*, and *AKT* (As shown in Figure 7). These proteins are involved in the major pathways regulating cell growth and proliferation.

## Discussion

Diosgenin is a well-known steroidal sapogenin that has been used in the treatment of cancers, inflammation, and infections due to its wide range of biological activities and medicinal properties [27, 28, 11]. It expresses by acting on different target proteins such as *CxCr4*, *COX-2*, *EF-kB*, *ERK*, *JNK*, *AKT*, etc. which regulate important processes in cancer cells like survival, invasion, proliferation, metastasis, chemoresistance, and cell death [19].

Notably, this is the first report to describe the anti-cancer potential of diosgenin against OSCC. Our findings demonstrated the efficacy of this steroidal sapogenin in influencing the viability, clonogenic potential, and migration of OSCC cells, potentially through the modulation of *AKT*, *COX-2*, and *CXCR4*-regulated gene products, which are pivotal in regulating various cell




Figure 4. Diosgenin Induced Cell Cycle Arrest in SAS Cells. (a) SAS cells were treated with 0, 20, and 40 µM diosgenin for 48 hours followed by flow cytometric analysis. (b) % cell count vs. Concentration was plotted. Data is presented as mean  $\pm$  SD, \* $p$  < 0.05 vs control.




Figure 5. Diosgenin Induces a Cytotoxic Effect on the SAS Oral Cancer Cells. (a) SAS cells were treated with 0, 5, 10, 25, 50, and 100  $\mu\text{M}$  diosgenin for 72 hours, followed by PI staining and FACS analysis for the cell death profile. (b) % cell death vs. Concentration was plotted. (c) Cytotoxic effect of diosgenin analysed by Live/Dead staining assay. SAS cells were treated with 0, 50, and 75  $\mu\text{M}$  diosgenin for 48 hours. The live cells are stained with calcein AM (green) and dead cells are stained with ethidium homodimer-1 (red). Data is presented as mean  $\pm$  SD, \* $p < 0.05$  vs control.

signalling pathways in cancer.

The current study suggests that diosgenin treatment exerts antiproliferative and cytotoxic effects on OSCC

cells. Similarly, previous findings indicate that diosgenin inhibits cell growth, induces cell cycle arrest, and activates apoptosis through p53 activation in various human cancer




Figure 6. Effect of Diosgenin on the Migration of SAS Cells. (a) SAS cells were treated with 0, 30, and 50  $\mu\text{M}$  diosgenin for 24 hours. (b) % wound area healed was calculated using ImageJ software. Data is presented as mean  $\pm$  SD, \* $p < 0.05$  vs control.




Figure 7. Effect of Diosgenin on Various Proteins Involved in OSCC. (a) SAS cells were treated with 0, 30, 50 and 75  $\mu$ M concentrations of diosgenin for 24 hours followed by Western blot analysis. (b) Densitometry plots of Fold change in expression vs. concentration were plotted. Blots were visualized and analyzed using Image Lab software. GAPDH was used as the housekeeping control. Data are presented as mean  $\pm$  SD, \* $p$  < 0.05 vs control.

cell lines, including laryngocarcinoma and melanoma cells [29]. Moreover, diosgenin has demonstrated antiproliferative activity in cervical cancer cells [30]. For instance, Selim and Al Jaouni, [31] observed that treatment of macrophages or lymphocytes with diosgenin (250 $\mu$ g/ml) led to a 3.2-fold and 2.1-fold induction in cell proliferation, respectively, compared to the control. Further, it decreased the ability of invasion and survival in cobalt chloride-treated BGC-823 cells effectively [32]. Diosgenin inhibited cell proliferation, induced G0/G1 phase arrest, and blocked IGF-1-induced cell proliferation in primary human thyroid cells [33].

Cytotoxicity refers to a sequence of molecular events disrupting macromolecular synthesis, causing substantial damage to cellular function and structure [34]. In this study, the anti-proliferative potential of diosgenin was examined in both normal (HEK-293T) and cancer cell lines (SAS and HSC3) using the MTT test. The MTT method is a sensitive indicator for assessing cytotoxicity, reflecting both cell number and metabolic activity, and is favoured for its simplicity, speed, repeatability, and lack of dependence on radioisotopes [22, 35, 36]. The results of cytotoxic studies revealed that the application of diosgenin led to a decrease in the percentage of cell proliferation in both cancer cell lines, while minimal changes were observed in the normal cell line. The  $IC_{50}$ , indicating

the concentration at which 50% of cells are inhibited, was determined for the SAS cell line as 31.7  $\mu$ M and for the HSC3 cell line as 61  $\mu$ M. The minimum inhibitory concentration against SAS cells significantly differed from that of normal epithelial lung (L132) cells, suggesting that this drug may pose a lower risk of damage to normal cells at appropriate doses. Additionally, the findings indicate that diosgenin demonstrates effectiveness against oral cancer cell lines over a broad concentration range.

Chemotherapy frequently results in undesirable side effects as the drugs lack the ability to differentiate between healthy and tumour cells, leading to harm to normal tissues. In this study, diosgenin was combined with well-established chemotherapeutic drugs, Cisplatin and 5-FU, to explore diosgenin's chemosensitizing effect. The combinations exhibited a synergistic effect on the anti-proliferative activity of diosgenin.

Diosgenin downregulated the expression of cancer-related protein markers such as *AKT*, *pAKT*, *VEGF*, *TWIST-1*, *COX-2*, and *CXCR-4*, indicating cancer suppressive role. These findings suggest that diosgenin can effectively regulate crucial cell signalling pathways to reduce tumour cell survival. *COX-2* is associated with carcinogen formation, tumour promotion, inhibition of apoptosis, angiogenesis, and the metastatic process [37]. It influences apoptosis, angiogenesis, and invasion, playing

a crucial role in carcinogen production. Typically, cancer cells exhibit high *COX-2* expression levels [38]. In vitro studies have shown the potential role of COX inhibitors as single agents in preventing tumour occurrence [39]. Liu et al. [40] were the first to describe tumorigenesis induced by *COX-2* overexpression. AKT/protein kinase B (PKB) is a central node in various signalling cascades crucial for normal cellular physiology and various disease states [41, 42]. AKT signalling regulates cell proliferation and survival, cell growth (size), glucose metabolism, cell motility, and angiogenesis [43]. In recent years, an expanding body of literature has documented the common occurrence of hyperactivation of AKT kinases across a wide spectrum of human solid tumors and hematological malignancies [44, 45]. Furthermore, a set of refined investigations employing animal models has illustrated that abnormal signaling through the AKT pathway can lead to malignancy either independently or in conjunction with specific genetic alterations, thereby promoting a more aggressive cancer phenotype [46, 47, 48]. Several oncoproteins and tumor suppressors interact with the AKT signal transduction pathway and become activated or deactivated, respectively, in cancer [49].

The collective findings from various studies emphasize the pivotal role of CXCR4 in OSCC and its potential impact on the diverse aspects of OSCC progression. Almofti et al. (2004) [50] proposed that the SDF-1/CXCR4 signalling pathway in oral squamous cell carcinoma cells may contribute to various actions of oral SCC, including invasion or micrometastasis at the primary site and lymph node metastasis. This aligns with the observations of Uchida et al. (2003) [51], who suggested a potential role of stromal-cell-derived factor-1/CXCR4 signalling in the lymph node metastasis of oral squamous cell carcinoma. The study conducted by Meng et al. (2010) [52] proposes CXCR4 as a novel biomarker for evaluating the biological behaviour of oral SCC. Furthermore, they suggest that CXCR4 inhibitors or antagonists could serve as potential anticancer agents to suppress tumour proliferation. Ishikawa et al. (2006) [53] found a highly significant correlation between CXCR4 expression and lymph node metastasis in OSCC, reinforcing the notion that CXCR4 may indeed play a crucial role in the lymph-node metastasis of oral squamous cell carcinoma. In line with these findings, Uchida et al. [54] suggested that the blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases, indicating the potential therapeutic utility of CXCR4 inhibition against metastatic spread. A study by Yu et al. (2011) [55] showed that the knockdown of CXCR4 significantly reduces Tca8113 cell migration and invasion, accompanied by a decrease in MMP-9 and MMP-13 expression. Additionally, the inhibition of ligand binding to CXCR4 by a specific antagonist (TN14003) led to reduced cancer cell migration and invasion, highlighting the potential of CXCR4 blockade as an anti-metastatic therapy against lymph node metastases in CXCR4-related OSCC [56]. The observed downregulation of CXCR4 aligns with the previously mentioned findings that highlight the crucial role of CXCR4 in different aspects of OSCC progression.

A study reported VEGF expression in OSCC tissues

and found a significant association between VEGF-A expression and tumour stage, as well as patient age. VEGF-A and VEGF-C were found to be overexpressed in OSCC, which were linked to tumour progression, invasion, and metastasis via the mTOR–HIF-1 $\alpha$ –VEGF pathway [57]. Another study has shown that VEGF can indirectly induce osteoclast formation by upregulating RANKL expression in OSCC cells via VEGF-Flt-1 signalling. This pathway may contribute to bone invasion commonly observed in OSCC cases [58]. A study demonstrated that TWIST1 overexpression in OSCC tissues correlates with higher rates of lymph node and lung metastases, as well as poorer patient survival suggesting its potential to serve as a prognostic marker for OSCC progression [59].

Our study also demonstrates that diosgenin effectively inhibits the proliferation of SAS oral cancer cells by inducing cell cycle arrest at the S-phase. This arrest leads to a concentration-dependent reduction in cell survival, colony formation, and migratory behaviour, as evidenced by MTT, colony formation and wound healing assays. Additionally, PI-FACS analysis revealed an increase in cell death percentages correlating with higher diosgenin concentrations. The induction of S-phase arrest by diosgenin aligns with findings in other cancer cell types. A study reported that diosgenin-treated HEp-2 cells exhibits S-phase arrest at 24 hours, while M4Beu cells showed G2/M phase arrest after 12 hours of treatment [60]. Beyond cell cycle arrest, diosgenin has been shown to inhibit migration and invasion in various cancer cells. In ovarian cancer cells (OVCAR-3), diosgenin treatment led to significant inhibition of cellular proliferation in a dose-dependent manner and decreased cell migration and invasion by modulating gene expression of invasion-related markers [61]. Similarly, Diosgenin induced G1 phase cell cycle arrest in both ER+ and ER– breast cancer cells by suppressing the expression of cyclin D1, CDK-2, and CDK-4, leading to inhibited cell proliferation and induction of apoptosis [62].

In conclusion, the plant saponin diosgenin has demonstrated significant anti-proliferative, cytotoxic, and anti-migratory effects by influencing various gene products such as *pAKT*, *AKT*, *VEGF*, *TWIST-1*, *COX-2*, and *CXCR-4*. These proteins are essential for the growth, survival, invasion, and metastasis of cancer cells, including OSCC, as was previously indicated. This study is the first to demonstrate diosgenin's anti-cancer properties in OSCC and the potential underlying mechanisms. However, further in vivo studies and clinical validation are required to validate the potential of this compound and the respective combination of drugs in order to design a novel drug that can effectively prevent and manage oral cancer progression and recurrence as well as successfully overcome chemoresistance.

## Author Contribution Statement

Uma Dutta contributed to the study design, conceptualisation, supervision, draft writing, review editing, material preparation, data collection, and analysis. Ajaikumar B. Kunnumakkara contributed to the study



design, fund acquisition, conceptualisation, review editing and laboratory facilities. Sonali Dey contributed to draft preparation, data analysis, figure and table preparation and bibliographic study. Monikongkona Baruah and Bethsebie Laldusaki Sailo contributed to data collection, table and figure preparation and some experimental part of work. Bhaigyaroti Muchahary contributed to bibliographic search and preparation. The first draft of the manuscript was written by Uma Dutta, Monikongkona Baruah, Sonali Dey and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

The authors are thankful to Department of Biosciences and Bioengineering, Indian Institute of Technology, Guwahati and Department of Zoology, Cotton University, for providing administrative and laboratory support to carry out the research work. The authors also express their gratitude to Miss Parama Dey for her assistance in some statistical analysis and graph and figure preparation of MTT assay.

## Funding

The authors acknowledge DBT-AIST International Center for Translational and Environmental Research (DAICENTER) for providing support to carry out the present work. This work was also supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2018R1D1A1B07042969).

## Data Availability

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary material. Raw data that support the findings of this study are available from the corresponding author, upon reasonable request.

## Ethical Declaration

This article does not contain any studies involving animals and human participants performed by any of the authors.

## Conflict of interest

The authors declare no conflict of interest.

## Abbreviations

OSCC: Oral Squamous Cell Carcinoma  
TNF- $\alpha$ : Tumor Necrosis Factor-alpha  
NF- $\kappa$ B: Nuclear Factor Kappa B  
5-FU: 5-Fluorouracil  
CIS: Cisplatin  
DMSO: Dimethyl Sulfoxide  
DMEM: Dulbecco's Minimum Essential Medium  
FBS: Fetal Bovine Serum  
PI: Propidium Iodide  
BSA: Bovine Serum Albumin  
MTT: 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide

PBS: Phosphate-Buffered Saline  
FACS: Fluorescence-Activated Cell Sorting  
SAS: Human Oral Squamous Cell Carcinoma Cell Line  
HSC3: Human Oral Squamous Cell Carcinoma Cell Line  
HEK-293T: Human Embryonic Kidney 293T Cells  
ECL: Enhanced Chemiluminescence  
SDS-PAGE: Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis  
TBST: Tris-Buffered Saline with Tween 20  
SD: Standard Deviation  
IC<sub>50</sub>: Half-Maximal Inhibitory Concentration  
PKB: Protein Kinase B  
RANKL: Receptor Activator of Nuclear Factor Kappa-B Ligand  
Flt-1: Fms-like Tyrosine Kinase-1

## References

1. Ettinger KS, Ganry L, Fernandes RP. Oral cavity cancer. *Oral Maxillofac Surg Clin North Am.* 2019;31(1):13-29. <https://doi.org/10.1016/j.coms.2018.08.002>.
2. Bugshan A, Farooq I. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. *F1000Res.* 2020;9:229. <https://doi.org/10.12688/f1000research.22941.1>.
3. Borse V, Konwar AN, Buragohain P. Oral cancer diagnosis and perspectives in India. *Sens Int.* 2020;1:100046. <https://doi.org/10.1016/j.sintl.2020.100046>.
4. Barnes L, editor. Pathology and genetics of head and neck tumours. IARC; 2005 pp 430.
5. Sreekumar VN. Global scenario of research in oral cancer. *J Maxillofac Oral Surg.* 2019;18(3):354-9. <https://doi.org/10.1007/s12663-018-1166-4>.
6. Eljabo N, Nikolic N, Carkic J, Jelovac D, Lazarevic M, Tanic N, et al. Genetic and epigenetic alterations in the tumour, tumour margins, and normal buccal mucosa of patients with oral cancer. *Int J Oral Maxillofac Surg.* 2018;47(8):976-82. <https://doi.org/10.1016/j.ijom.2018.01.020>.
7. Lorini L, Bescós Atín C, Thavaraj S, Müller-Richter U, Alberola Ferranti M, Pamias Romero J, et al. Overview of oral potentially malignant disorders: from risk factors to specific therapies. *Cancers.* 2021;13(15):3696. <https://doi.org/10.3390/cancers13153696>.
8. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. *Int J Cancer.* 2008;122(1):155-64. <https://doi.org/10.1002/ijc.23033>.
9. Wijdeven RH, Pang B, Assaraf YG, Neefjes J. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics. *Drug Resist Updat.* 2016;28:65-81. <https://doi.org/10.1016/j.drug.2016.07.001>.
10. Aware CB, Patil DN, Suryawanshi SS, Mali PR, Rane MR, Gurav RG, et al. Natural bioactive products as promising therapeutics: A review of natural product-based drug development. *S Afr J Bot.* 2022;151:512-28. <https://doi.org/10.1016/j.sajb.2022.05.028>.
11. Raju J, Mehta R. Cancer chemopreventive and therapeutic effects of diosgenin, a food saponin. *Nutr Cancer.* 2009;61(1):27-35. <https://doi.org/10.1080/01635580802357352>.
12. Muchahary B, Dutta U. Documentation on ethnomedicinal usages of different Dioscorea species (Yams) amongst the people of Bodoland Territorial Region, Assam, India. *Journal of Biodiversity and Environmental Sciences.*

- 2022;21(5):46-55.
13. Srivastava RC. Traditional knowledge of Nyishi (Daffla) tribe of Arunachal Pradesh. *Indian J Tradit Knowl*. 2010;9(1):26-37.
14. Dutta B. Food and medicinal values of certain species of Dioscorea with special reference to Assam. *J Pharmacogn Phytochem*. 2015;3(5).
15. Parama D, Boruah M, Yachna K, Rana V, Banik K, Harsha C, et al. Diosgenin, a steroidal saponin, and its analogs: Effective therapies against different chronic diseases. *Life sci*. 2020;260:118182. <https://doi.org/10.1016/j.lfs.2020.118182>
16. Mondal S. Anticancer Potential of Biologically Active Diosgenin and its Derivatives: An Update. *Curr Tradit Med*. 2024;10(1):67-80. <https://doi.org/10.2174/2215083809666230202143136>
17. Nguyen LT, Farcas AC, Socaci SA, Tofana M, Diaconeasa ZM, Pop OL, et al. An overview of Saponins—a bioactive group. *B UASVM-Food Sci Te*. 2020;77(1):25-36. <https://doi.org/10.15835/buasvmcn-fst.2019.0036>.
18. Upadhyay S, Jeena GS, Shikha, Shukla RK. Recent advances in steroidal saponins biosynthesis and *in vitro* production. *Planta*. 2018;248(3):519-44. <https://doi.org/10.1007/s00425-018-2911-0>
19. Jung DH, Park HJ, Byun HE, Park YM, Kim TW, Kim BO, et al. Diosgenin inhibits macrophage-derived inflammatory mediators through downregulation of CK2, JNK, NF- $\kappa$ B and AP-1 activation. *Int Immunopharmacol*. 2010;10(9):1047-54. <https://doi.org/10.1016/j.intimp.2010.06.004>
20. Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I $\kappa$ B kinase activation and NF- $\kappa$ B-regulated gene expression. *Oncogene*. 2006;25(10):1463-73. <https://doi.org/10.1038/sj.onc.1209194>
21. Xu Q, Cao Z, Xu J, Dai M, Zhang B, Lai Q, et al. Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases. *J Drug Target*. 2022;30(4):394-412. <https://doi.org/10.1080/1061186X.2021.2013488>
22. Tolosa L, Donato MT, Gómez-Lechón MJ. General cytotoxicity assessment by means of the MTT assay. *Methods Mol Biol*. 2015;333-48. [https://doi.org/10.1007/978-1-4939-2074-7\\_26](https://doi.org/10.1007/978-1-4939-2074-7_26)
23. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nat Protoc*. 2006;1(3):1458-61. <https://doi.org/10.1038/nprot.2006.238>
24. Chan LL, McCulley KJ, Kessel SL. Assessment of cell viability with single-, dual-, and multi-staining methods using image cytometry. *Methods Mol Biol*. 2017;1601:27-41. [https://doi.org/10.1007/978-1-4939-6960-9\\_3](https://doi.org/10.1007/978-1-4939-6960-9_3).
25. Jonkman JE, Cathcart JA, Xu F, Bartolini ME, Amon JE, Stevens KM, et al. An introduction to the wound healing assay using live-cell microscopy. *Cell Adh Migr*. 2014;8(5):440-51. <https://doi.org/10.4161/cam.36224>
26. Arunachalam K, Sasidharan SP, Arunachalam K, Sasidharan SP. Protein Extraction and Western Blot Analysis. *Bioassays in Experimental and Preclinical Pharmacology*. 2021:229-40. [https://doi.org/10.1007/978-1-0716-1233-0\\_22](https://doi.org/10.1007/978-1-0716-1233-0_22)
27. Cai B, Zhang Y, Wang Z, Xu D, Jia Y, Guan Y, et al. Therapeutic potential of diosgenin and its major derivatives against neurological diseases: recent advances. *Oxid Med Cell Longev*. 2020(1):3153082. <https://doi.org/10.1155/2020/3153082>
28. Jesus M, Martins AP, Gallardo E, Silvestre S. Diosgenin: recent highlights on pharmacology and analytical methodology. *J Anal Methods Chem*. 2016;2016(1):4156293. <https://doi.org/10.1155/2016/4156293>
29. Corbiere C, Liagre B, Terro F, Beneytout JL. Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. *Cell Res*. 2004;14(3):188-96. <https://doi.org/10.1038/sj.cr.7290219>
30. Hernández-Vázquez JM, López-Muñoz H, Escobar-Sánchez ML, Flores-Guzmán F, Weiss-Steider B, Hilario-Martínez JC, et al. Apoptotic, necrotic, and antiproliferative activity of diosgenin and diosgenin glycosides on cervical cancer cells. *Eur J Pharmacol*. 2020;871:172942. <https://doi.org/10.1016/j.ejphar.2020.172942>
31. Selim S, Al Jaouni S. Anticancer and apoptotic effects on cell proliferation of diosgenin isolated from *Costus speciosus* (Koen.) Sm. *BMC Complement Altern Med*. 2015;15:1-7. <https://doi.org/10.1186/s12906-015-0836-8>
32. Mao ZJ, Tang QJ, Zhang CA, Qin ZF, Pang B, Wei PK, et al. Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1 $\alpha$  shRNAs. *Int J Mol Sci*. 2012;13(5):6521-33. <https://doi.org/10.3390/ijms13056521>
33. Bian D, Li Z, Ma H, Mu S, Ma C, Cui B, et al. Effects of diosgenin on cell proliferation induced by IGF-1 in primary human thyrocytes. *Arch Pharm Res*. 2011;34:997-1005. <https://doi.org/10.1007/s12272-011-0617-y>
34. León-Mejía G, Guevara AM, Moreno OF, Cruz CU. Cytotoxicity as a fundamental response to xenobiotics. *Cytotoxicity-New Insights into Toxic Assessment*. 2021:7. <https://doi.org/10.5772/intechopen.96239>
35. Kumar P, Nagarajan A, Uchil PD. Analysis of cell viability by the MTT assay. *Cold Spring Harb. Protoc*. 2018;2018(6):pdb-rot095505. <https://doi.org/10.1101/pdb.prot095505>
36. Van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. *Methods Mol Biol*. 2011:237-45. [https://doi.org/10.1007/978-1-61779-080-5\\_20](https://doi.org/10.1007/978-1-61779-080-5_20)
37. Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase-2 in cancer: a review. *J Cell Physiol*. 2019;234(5):5683-99. <https://doi.org/10.1002/jcp.27411>
38. Tudor DV, Bâldea I, Lupu M, Kacso T, Kutasi E, Hopârtean A, et al. COX-2 as a potential biomarker and therapeutic target in melanoma. *Cancer Biol Med*. 2020;17(1):20-31. <https://doi.org/10.20892%2Fj.issn.2095-3941.2019.0339>
39. Li S, Jiang M, Wang L, Yu S. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement. *Biomed Pharmacother*. 2020;129:110389. <https://doi.org/10.1016/j.biopha.2020.110389>
40. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. *J Biol Chem*. 2001;276(21):18563-9. <https://doi.org/10.1074/jbc.M010787200>
41. Islam M, Jones S, Ellis I. Role of akt/protein kinase B in cancer metastasis. *Biomedicines*. 2023;11(11):3001. <https://doi.org/10.3390/biomedicines11113001>
42. Sale EM, Sale GJ. Protein kinase B: signalling roles and therapeutic targeting. *Cell Mol Life Sci*. 2008;65:113-27. <https://doi.org/10.1007/s00018-007-7274-9>
43. Bellacosa A, Testa JR, Moore R, Larue L. A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. *Cancer Biol Ther*. 2004;3(3):268-75. <https://doi.org/10.4161/cbt.3.3.703>
44. Cantley LC. The phosphoinositide 3-kinase pathway. *Science*. 2002;296(5573):1655-7. <https://doi.org/10.1126/science.296.5573.1655>
45. Testa JR, Bellacosa A. AKT plays a central role in

- tumorigenesis. *Proc Natl Acad Sci U S A*. 2001;98(20):10983-5. <https://doi.org/10.1073/pnas.211430998>
46. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. *Adv Cancer Res*. 2005;94:29-86. [https://doi.org/10.1016/S0065-230X\(05\)94002-5](https://doi.org/10.1016/S0065-230X(05)94002-5)
  47. He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K/Akt signal transduction for cancer therapy. *Signal Transduct Target Ther*. 2021;6(1):425. <https://doi.org/10.1038/s41392-021-00828-5>
  48. Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M. PI3K/Akt signalling pathway and cancer. *Cancer Treat Rev*. 2004;30(2):193-204. <https://doi.org/10.1016/j.ctrv.2003.07.007>
  49. Testa JR, Tsichlis PN. AKT signaling in normal and malignant cells. *Oncogene*. 2005;24(50):7391-3. <https://doi.org/10.1038/sj.onc.1209100>
  50. Almofti A, Uchida D, Begum NM, Tomizuka Y, Iga H, Yoshida H, et al. The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. *Int J Oncol*. 2004;25(1):65-71. <https://doi.org/10.3892/ijo.25.1.65>
  51. Uchida D, Begum NM, Almofti A, Nakashiro KI, Kawamata H, Tateishi Y, et al. Possible role of stromal-cell-derived factor-1/CXCR4 signaling on lymph node metastasis of oral squamous cell carcinoma. *Experimental cell research*. 2003;290(2):289-302. [https://doi.org/10.1016/S0014-4827\(03\)00344-6](https://doi.org/10.1016/S0014-4827(03)00344-6)
  52. Meng X, Wuyi L, Yuhong X, Xinming C. Expression of CXCR4 in oral squamous cell carcinoma: correlations with clinicopathology and pivotal role of proliferation. *J Oral Pathol Med*. 2010;39(1):63-8. <https://doi.org/10.1111/j.1600-0714.2009.00801.x>
  53. Ishikawa T, Nakashiro KI, Hara S, Klosek SK, Li C, Shintani S, et al. CXCR4 expression is associated with lymph-node metastasis of oral squamous cell carcinoma. *Int J Oncol*. 2006;28(1):61-6. <https://doi.org/10.3892/ijo.28.1.61>
  54. Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H, et al. Blockade of cxcr4 in oral squamous cell carcinoma inhibits lymph node metastases. *Eur J Cancer*. 2011;47(3):452-9. <https://doi.org/10.1016/j.ejca.2010.09.028>
  55. Yu T, Wu Y, Helman JJ, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. *Mol Cancer Res*. 2011;9(2):161-72. <https://doi.org/10.1158/1541-7786.MCR-10-0386>
  56. Tsutsumi H, Tanaka T, Ohashi N, Masuno H, Tamamura H, Hiramatsu K, et al. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. *Biopolymers*. 2007;88(2):279-89. <https://doi.org/10.1002/bip.20653>
  57. Naruse T, Kawasaki G, Yanamoto S, Mizuno A, Umeda M. Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: correlation with the mTOR-HIF-1 $\alpha$  pathway. *Anticancer Res*. 2011;31(12):4429-37.
  58. Subarnbhesaj A, Miyauchi M, Chanbora C, Mikuriya A, Nguyen PT, Furusho H, et al. Roles of VEGF-Flt-1 signaling in malignant behaviors of oral squamous cell carcinoma. *PLoS One*. 2017;12(11):e0187092. <https://doi.org/10.1371/journal.pone.0187092>
  59. Da Silva SD, Alaoui-Jamali MA, Soares FA, Carraro DM, Brentani HP, Hier M, et al. TWIST1 is a molecular marker for a poor prognosis in oral cancer and represents a potential therapeutic target. *Cancer*. 2014;120(3):352-62. <https://doi.org/10.1002/cncr.28404>
  60. Corbiere C, Liagre B, Terro F, Beneytout JL. Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells. *Cell Res*. 2004;14(3):188-96. <https://doi.org/10.1038/sj.cr.7290219>
  61. Fang F, Zhang X, Fang Y. Diosgenin inhibits proliferation and migration of ovarian cancer cells and induce apoptosis via upregulation of PTEN. *Chem Biol Drug Des*. 2024;103(3):e14459. <https://doi.org/10.1111/cbdd.14459>
  62. Srinivasan S, Koduru S, Kumar R, Venguswamy G, Kyprianou N, Damodaran C. Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. *Int J Cancer*. 2009;125(4):961-7. <https://doi.org/10.1002/ijc.24419>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.